Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 11 | 2018 | 32 | 3.280 |
Why?
|
| Arthroplasty, Replacement, Hip | 11 | 2017 | 49 | 3.190 |
Why?
|
| Prosthesis-Related Infections | 9 | 2017 | 24 | 3.140 |
Why?
|
| Hip Prosthesis | 8 | 2016 | 59 | 3.020 |
Why?
|
| Prosthesis Failure | 8 | 2016 | 51 | 1.700 |
Why?
|
| Synovial Fluid | 6 | 2016 | 23 | 1.670 |
Why?
|
| Aged | 19 | 2017 | 898 | 1.440 |
Why?
|
| Middle Aged | 18 | 2017 | 756 | 1.380 |
Why?
|
| C-Reactive Protein | 6 | 2016 | 25 | 1.280 |
Why?
|
| Hip Joint | 4 | 2014 | 38 | 1.230 |
Why?
|
| Male | 20 | 2017 | 1781 | 1.200 |
Why?
|
| Female | 19 | 2017 | 1644 | 1.180 |
Why?
|
| Adult | 14 | 2016 | 759 | 1.130 |
Why?
|
| Analgesia, Epidural | 2 | 2018 | 14 | 1.110 |
Why?
|
| Humans | 21 | 2018 | 2822 | 1.100 |
Why?
|
| Aged, 80 and over | 12 | 2016 | 540 | 1.090 |
Why?
|
| Periprosthetic Fractures | 3 | 2016 | 6 | 0.980 |
Why?
|
| Treatment Outcome | 13 | 2017 | 182 | 0.950 |
Why?
|
| Reoperation | 11 | 2017 | 37 | 0.930 |
Why?
|
| Pain, Postoperative | 5 | 2017 | 47 | 0.890 |
Why?
|
| Hip Dislocation | 2 | 2015 | 6 | 0.870 |
Why?
|
| Arthritis, Infectious | 2 | 2016 | 6 | 0.870 |
Why?
|
| Pain Management | 2 | 2018 | 27 | 0.680 |
Why?
|
| Retrospective Studies | 7 | 2015 | 165 | 0.640 |
Why?
|
| Blood Sedimentation | 5 | 2016 | 14 | 0.570 |
Why?
|
| Knee Prosthesis | 2 | 2014 | 15 | 0.540 |
Why?
|
| Nerve Block | 1 | 2017 | 20 | 0.540 |
Why?
|
| Prospective Studies | 7 | 2016 | 197 | 0.530 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 1 | 0.520 |
Why?
|
| Osteoarthritis, Knee | 2 | 2014 | 48 | 0.510 |
Why?
|
| Hemoglobins | 1 | 2016 | 2 | 0.500 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 2 | 0.500 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 6 | 0.490 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 7 | 0.490 |
Why?
|
| Leukocyte Count | 4 | 2016 | 13 | 0.480 |
Why?
|
| Femur Head | 1 | 2015 | 10 | 0.470 |
Why?
|
| Metal-on-Metal Joint Prostheses | 1 | 2015 | 5 | 0.460 |
Why?
|
| Malnutrition | 1 | 2015 | 2 | 0.460 |
Why?
|
| Arthroplasty, Replacement | 1 | 2015 | 6 | 0.460 |
Why?
|
| Nutritional Status | 1 | 2015 | 18 | 0.450 |
Why?
|
| Joint Prosthesis | 1 | 2015 | 8 | 0.450 |
Why?
|
| Sepsis | 1 | 2015 | 12 | 0.450 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 4 | 0.440 |
Why?
|
| Osteotomy | 1 | 2014 | 9 | 0.440 |
Why?
|
| Risk Factors | 5 | 2015 | 263 | 0.420 |
Why?
|
| Microbiological Techniques | 1 | 2013 | 2 | 0.410 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 3 | 0.410 |
Why?
|
| Drainage | 1 | 2013 | 14 | 0.410 |
Why?
|
| Femoral Fractures | 1 | 2012 | 8 | 0.390 |
Why?
|
| ROC Curve | 3 | 2016 | 20 | 0.340 |
Why?
|
| Logistic Models | 3 | 2016 | 59 | 0.340 |
Why?
|
| Time Factors | 4 | 2015 | 205 | 0.310 |
Why?
|
| Analgesia | 3 | 2016 | 10 | 0.300 |
Why?
|
| Biomarkers | 3 | 2014 | 91 | 0.300 |
Why?
|
| Pain Measurement | 5 | 2017 | 54 | 0.290 |
Why?
|
| Walking | 2 | 2018 | 12 | 0.280 |
Why?
|
| Analgesics, Opioid | 2 | 2017 | 34 | 0.260 |
Why?
|
| Metals | 2 | 2016 | 9 | 0.250 |
Why?
|
| Recovery of Function | 3 | 2017 | 15 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2017 | 32 | 0.230 |
Why?
|
| Area Under Curve | 2 | 2014 | 10 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 59 | 0.220 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 48 | 0.220 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 73 | 0.200 |
Why?
|
| Knee Joint | 2 | 2013 | 39 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2013 | 222 | 0.190 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 5 | 0.170 |
Why?
|
| Analgesics | 2 | 2011 | 20 | 0.170 |
Why?
|
| Awards and Prizes | 2 | 2017 | 4 | 0.160 |
Why?
|
| Administration, Oral | 2 | 2017 | 13 | 0.160 |
Why?
|
| Femoral Nerve | 1 | 2018 | 2 | 0.140 |
Why?
|
| Double-Blind Method | 2 | 2016 | 46 | 0.140 |
Why?
|
| Thigh | 1 | 2017 | 3 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2017 | 7 | 0.140 |
Why?
|
| Anesthesia, Conduction | 1 | 2017 | 4 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 14 | 0.140 |
Why?
|
| Pain | 1 | 2018 | 47 | 0.140 |
Why?
|
| Vasculitis | 1 | 2016 | 5 | 0.130 |
Why?
|
| Morphine | 1 | 2016 | 12 | 0.120 |
Why?
|
| Ketorolac | 1 | 2016 | 5 | 0.120 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cost Savings | 1 | 2016 | 3 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 5 | 0.120 |
Why?
|
| Joints | 1 | 2016 | 13 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 9 | 0.120 |
Why?
|
| Neutrophils | 1 | 2016 | 16 | 0.120 |
Why?
|
| Dexamethasone | 1 | 2016 | 11 | 0.120 |
Why?
|
| Bupivacaine | 1 | 2016 | 14 | 0.120 |
Why?
|
| Research Design | 1 | 2016 | 21 | 0.120 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 30 | 0.120 |
Why?
|
| Arthralgia | 1 | 2016 | 25 | 0.120 |
Why?
|
| Polyethylene | 1 | 2015 | 12 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 139 | 0.120 |
Why?
|
| Corrosion | 1 | 2015 | 9 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 17 | 0.110 |
Why?
|
| Nutrition Assessment | 1 | 2015 | 19 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2015 | 30 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 26 | 0.110 |
Why?
|
| Operative Time | 1 | 2014 | 5 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 1 | 0.100 |
Why?
|
| Osteoarthritis, Hip | 1 | 2013 | 5 | 0.100 |
Why?
|
| Chicago | 2 | 2011 | 148 | 0.100 |
Why?
|
| Prevalence | 1 | 2012 | 39 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 8 | 0.090 |
Why?
|
| Prognosis | 1 | 2012 | 39 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 68 | 0.090 |
Why?
|
| Age Factors | 1 | 2012 | 84 | 0.090 |
Why?
|
| Substance P | 1 | 2011 | 4 | 0.090 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 4 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2012 | 49 | 0.090 |
Why?
|
| Norepinephrine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Glutamic Acid | 1 | 2011 | 6 | 0.090 |
Why?
|
| Young Adult | 1 | 2012 | 179 | 0.090 |
Why?
|
| Adolescent | 1 | 2012 | 241 | 0.090 |
Why?
|
| Length of Stay | 1 | 2010 | 14 | 0.080 |
Why?
|
| Acetabulum | 1 | 2009 | 25 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 14 | 0.050 |
Why?
|
| Pregabalin | 2 | 2011 | 4 | 0.040 |
Why?
|
| Recurrence | 1 | 2017 | 8 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 3 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2016 | 2 | 0.030 |
Why?
|
| Injections | 1 | 2016 | 10 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 17 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2016 | 20 | 0.030 |
Why?
|
| Motor Activity | 1 | 2016 | 51 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 161 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 167 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 978 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 5 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 53 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 16 | 0.020 |
Why?
|
| Tibia | 1 | 2013 | 34 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 105 | 0.020 |
Why?
|
| Femur | 1 | 2013 | 103 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2011 | 2 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2011 | 3 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2011 | 7 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2009 | 4 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 28 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2009 | 29 | 0.020 |
Why?
|
| Sleep | 1 | 2009 | 49 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2009 | 30 | 0.020 |
Why?
|